DSS, INC. Annual Report - How They Did This Year

I’m writing this guide to help you understand how DSS, Inc. performed this year. My goal is to cut through the corporate jargon and give you the facts you need to decide if this company fits your investment goals.

1. What does this company do?

DSS, Inc. is a diversified holding company that operates across four main areas:

• Product Packaging: Their main revenue source, Premier Packaging, makes custom boxes, labels, and security printing for the medical, food, and beauty industries.
• Biotechnology: Their subsidiary, Impact BioMedical, develops drug platforms, sugar substitutes, and specialized fragrance technologies.
• Commercial Lending: They provide loans and financing to small and medium-sized businesses.
• Securities & Investment Management: They manage broker-dealer activities through Sentinel Brokers and hold various real estate assets, including commercial properties and land.

2. Financial performance & health

The company is currently in a rebuilding phase, focusing on cash management and asset optimization.

• Revenue Trends: For the year ending December 31, 2024, the company reported approximately $145 million in revenue. Early 2025 growth was driven by a 12% increase in packaging volume and a 5% rise in rental income.
• Asset Management: To improve liquidity, the company is selling non-core assets. In 2024, they sold a Texas manufacturing plant for $9.5 million, allocating $4.2 million of those proceeds to pay down high-interest debt.
• The "Three-Stage" Plan: Management’s strategy involves acquiring distressed assets, improving their operations to reach profitability, and spinning them off through IPOs or mergers to unlock shareholder value.
• Cost Cutting: Management has initiated a plan to reduce corporate overhead and administrative expenses by 15-20% by late 2025 to address the $48 million loss reported last year.

3. Major wins and challenges

• Wins: Sentinel Brokers received approval to act as an underwriter for IPOs, creating a potential new stream of fee income. Additionally, the packaging division successfully transitioned 15% of its client base to higher-margin medical packaging, which boosted profit margins by 2.5%.
• Complexity: The company operates as a complex web of internal loans and shared services. Investors should note that this structure makes it difficult to distinguish between natural growth and the movement of capital between subsidiaries.
• Transparency: The company has previously issued corrections to past financial reports. They currently report "material weaknesses" in their internal controls, indicating that their systems for financial reporting are still being strengthened.

4. Key risks for investors

• Speculative Nature: With a market value often below $50 million, the stock is highly volatile. This can make it difficult to buy or sell shares in large quantities without impacting the share price.
• Debt & Control: The company maintains a debt-to-equity ratio exceeding 2.5 to 1. The presence of material weaknesses in internal controls also increases the risk of regulatory scrutiny or future financial restatements.
• Execution Risk: The long-term strategy relies heavily on the successful spin-off of subsidiaries like Impact BioMedical. If the IPO market remains stagnant or if regulatory hurdles arise, the company may be left holding cash-burning assets without a clear path to profitability.

Bottom Line for Investors: DSS, Inc. is a high-risk, speculative play currently undergoing a significant operational turnaround. Success depends entirely on management’s ability to cut costs, stabilize their internal financial controls, and successfully spin off their subsidiary businesses. Before investing, consider whether you are comfortable with the risks associated with their high debt levels and the complexity of their corporate structure.